Akèy › Maladi otoim › Tennessee
Etid klinik pou Maladi otoim nan Tennessee
10 etid pou Maladi otoim ap chèche patisipan nan sit nan Tennessee.
Vil nan Tennessee
Tèks ofisyèl etid la (Anglè)
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
- West Tennessee Research Institute, Jackson
- Shelby Research LLC, Memphis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07621809RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- Vanderbilt University Medical Center - Accepting Adult Patients, Nashville
Ap rekriteFaz 2/3
Laj 6 a 75 · Tout sèks · Mizajou Sep 17, 2026 · NCT06154252Abatacept for the Treatment of Giant Cell Arteritis
- Vanderbilt University, Nashville
Ap rekriteFaz 3
Laj 50 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT04474847Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
- Knoxville Kidney Center Pllc, Brentwood
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Aug 17, 2026 · NCT06858319A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
- St. Jude Childrens; Research Hospital, Memphis
Ap rekriteFaz 3
Laj 12 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT06056297Study of BHV-1300 in Graves' Disease
- Site-107, Memphis
Ap rekriteFaz 1
Laj 18 a 65 · Tout sèks · Mizajou Jul 31, 2026 · NCT06980649Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1021, Memphis
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Jul 30, 2026 · NCT07039916A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- St. Jude Childrens Research Hospital, Memphis
- Vanderbilt University, Nashville
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jul 6, 2026 · NCT01351545A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Regional One Health, Memphis
Ap rekriteFaz 1
Laj 12 a 70 · Tout sèks · Mizajou May 22, 2026 · NCT06308978Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease
- Toyos Clinic, Nashville
Ap rekriteFaz 4Volontè an sante akeyi
Laj 18 a 85 · Tout sèks · Mizajou May 11, 2025 · NCT06964269Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.